Cretostimogene Grenadenorepvec

Phase 2Recruiting

0 views this week 0 watching💤 Quiet

Interest: 39/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

High-Risk Non-Muscle-Invasive Bladder Cancer

Conditions

High-Risk Non-Muscle-Invasive Bladder Cancer

Trial Timeline

Sep 16, 2024 → Dec 30, 2027

NCT ID

NCT06567743

About Cretostimogene Grenadenorepvec

Cretostimogene Grenadenorepvec is a phase 2 stage product being developed by CG Oncology for High-Risk Non-Muscle-Invasive Bladder Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06567743. Target conditions include High-Risk Non-Muscle-Invasive Bladder Cancer.

What happened to similar drugs?

0 of 5 similar drugs in High-Risk Non-Muscle-Invasive Bladder Cancer were approved

Approved (0) Terminated (1) Active (4)

🔄SHR3680 + PlaceboJiangsu Hengrui MedicinePhase 3

🔄DAPA/MET XR + DAPA + MET XRAstraZenecaPhase 3

🔄Pembrolizumab + BCGMerckPhase 3

🔄Axicabtagene Ciloleucel + Cyclophosphamide + Fludarabine + Etoposide + Rituximab + Doxorubicin + Vincristine + PrednisoneGilead SciencesPhase 3

❌EsmololBaxterPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06443944	Pre-clinical	Active	—	—	Non-Muscle Invasive Bladder Cancer
NCT06567743	Phase 2	Recruiting	Sep 16, 2024	Dec 30, 2027	High-Risk Non-Muscle-Invasive Bladder Cancer
NCT06111235	Phase 3	Active	Dec 14, 2023	Feb 1, 2029	Non Muscle Invasive Bladder Cancer
NCT04452591	Phase 3	Active	Oct 27, 2020	Dec 24, 2031	Non Muscle Invasive Bladder Cancer

Competing Products

13 competing products in High-Risk Non-Muscle-Invasive Bladder Cancer

See all competitors

Product	Company	Stage	Hype Score
GTB-3550 TriKE® Phase I + GTB-3550 TriKE® Phase II	GT Biopharma	Phase 1/2	14
SHR3680 + Placebo	Jiangsu Hengrui Medicine	Phase 3	47
DAPA/MET XR + DAPA + MET XR	AstraZeneca	Phase 3	40
Pembrolizumab + BCG	Merck	Phase 3	44
Blinatumomab + Investigator's Choice Chemotherapy + Dexamethasone	Amgen	Phase 2	35
Blinatumomab	Amgen	Phase 2	27
Axicabtagene Ciloleucel + Cyclophosphamide + Fludarabine + Etoposide + Rituximab + Doxorubicin + Vincristine + Prednisone	Gilead Sciences	Phase 3	47
Darolutamide + ADT	Bayer	Phase 2	39
Esmolol	Baxter	Phase 3	29
N-803 (IL-15 Superagonist) + ETBX-071 (PSA-based Oncolytic Virus) + M-CENK (Activated NK Cells)	ImmunityBio	Phase 2	39
N-803 + ETBX-071 + M-CENK	ImmunityBio	Phase 2	39
RP2 Injection	Replimune	Phase 2	36
R-enantiomer of 1,2-dioleoyl-3-trimethylammonium-propane chloride + Peptides from HPV-16 E6 and E7	PDS Biotechnology	Phase 1	19